In the News
ICON experts frequently author or contribute to industry trade press.
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category.
-
Data integration frameworks key for embracing big data’s potential
Rick Rosenthal and Paula Fullman of Symphony Health, an ICON plc company, explain how to navigate the complexities and challenges of the evolving digital landscape of healthcare data in this article from PharmaTimes.
-
Winners recognised amid record entries for the PwC Business Post Sustainable Business Awards
This article in the Business Post lists ICON as the winner of the Social and Equality Business of the Year Award category of the 2024 PwC Business Post Sustainable Business Awards.
-
Clinical development strategy in oncology
In Dr Tanja Obradovic's article in The Cancer Letter, she discusses how to navigate early clinical development and support robust registrational strategy and late-stage development in oncology.
-
Seeking solutions for more representative populations
This article in Applied Clinical Trials by Tinaya Gray, Global Head of Diversity & Inclusion in Clinical Trials discusses how technology can offer opportunities to leverage tailored solutions that can help drive inclusive diversity in clinical research, to help increase participation from underrepresented patient populations.
-
Insight into obesity-related clinical research
In an interview with Contract Pharma, ICON’s Adrienne Stoudenmire and Alan Baldridge discuss current obesity R&D trends, challenges associated with obesity-related clinical research, and opportunities in this sector.
-
The State of Obesity-Related Clinical Research: A Q&A session with ICON's Simon Bruce
ICON’s Simon Bruce, Vice President of Internal Medicine and Drug Development Solutions sits down for a Q&A with Pharmaceutical Executive and gives an overview on the obesity survey carried out by ICON in January 2024 and what it suggests about the state of the obesity-related pipeline.
-
A new chapter for biotech: Confidence returns to the market
In this article from Fierce Biotech, Chris Smyth, President of ICON Biotech outlines reasons for optimism in 2024, as the biotech sector looks to bounce back after several challenging years.
-
Revolutionising Drug Development: Key Takeaways from the ICON Biotech Survey
In this article from The Journal of mHealth, Chris Smyth, President of ICON Biotech, dissects the challenges and opportunities discovered in ICON's recent biotech sector survey. He explores strategies for accelerating the drug development process, emphasising the potential of partnerships to strategically support biotech companies, how organisations are addressing the current funding challenges and the industry’s overall commitment to addressing unmet healthcare needs.
-
ICON acquires HumanFirst to boost support for digital tools in clinical trials
This article from STAT covers ICON’s acquisition of HumanFirst, a cloud-based technology company supporting precision measurement in clinical trials. It features an interview with Andy Coravos, CEO of HumanFirst, who outlines how the acquisition will support sponsors to deploy better and more effective precision measurements into more clinical trials.
-
A pandemic-era staffing crunch in clinical trials is easing, but trouble spots remain
In an interview with PharmaVoice, Helen Yeardley, SVP, Global Clinical Operations outlines how the hiring landscape for CRAs has improved markedly, and the ongoing importance of attracting new candidates and providing training.
